AI star comes up trumps again with new drug candidate

18 August 2021
biotech_lab_big

Artificial intelligence-driven pharma company Exscientia has taken another step forward in a major collaboration with New York-based Bristol Myers Squibb (NYSE: BMY).

The oncology giant has elected to in-license an immune-modulating drug candidate created by Exscientia, adding to its existing work with the Oxford, UK-based company.

The firms are now collaborating in multiple therapeutic areas, including oncology and immunology, and a significant expansion of the relationship was announced earlier in 2021.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


More Features in Pharmaceutical